Ecuador's medicines regulator. It grants the registro sanitario a medicine needs to be sold, with a shortened route for medicines already registered by strict foreign regulators, and in 2025 began a WHO maturity level 3 pre-assessment with PAHO.
ARCSA, headquartered at Parque Samanes in Guayaquil, grants the registro sanitario (marketing authorisation) for medicines on behalf of the national health authority. Its procedure for foreign-made medicines by homologation defines homologation as the official recognition of registrations granted by countries whose regulators ARCSA lists as high health-surveillance agencies, and of medicines prequalified by WHO; the route is open only to medicines on the current Cuadro Nacional de Medicamentos Básicos, and the certificate lasts five years. The fee listed on gob.ec is 2,258.41 dollars for a foreign medicine, 565.21 for a foreign generic and 452.17 for a generic on the national list. The coordinates are approximate.
PAHO wrote in October 2024 that ARCSA had begun a process to be certified under WHO's Global Benchmarking Tool as a maturity level 3 authority, and in May 2025 that it had started the pre-assessment, accompanied by PAHO and WHO staff. On 31 August 2026 the Ministry of Public Health announced a 7.4 million dollar project to renew ARCSA's vehicles and equipment for its reference laboratories in Quito, Guayaquil and Cuenca, with the aim of certification as a regional reference regulator by PAHO and WHO. The Ley Orgánica para la Atención Integral del Cáncer of March 2026 provides, according to legal summaries, a conditional registration for medicines for serious disease where the benefit outweighs the risk on preliminary evidence.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/